Ninety-two percent of pancreatic cancers with KRAS mutations can promote the recruitment of MDSCs and Tregs through the secretion of cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) [148,149,150]. This evidence concerns the gene CSF2 and familial pancreatic carcinoma.